This article is more than 5 years old. Information may no longer be current.
Ophthalmic solution safe, effective in treating allergic conjunctivitis
SAN FRANCISCO — A number of posters here showed the safety and effectiveness of bepotastine besilate ophthalmic solution 1.5% in the reduction of ocular itching due to allergic conjunctivitis.
In a poster presentation at the American Society of Cataract and Refractive Surgery meeting, Mark T. Bergmann, MD, and colleagues showed Bepreve (bepotastine besilate ophthalmic solution 1.5%, Ista Pharmaceuticals) reduced ocular itching in a multisite clinical model.
Dr. Bergmann and colleagues used the conjunctival allergen challenge (CAC) model in a multicenter, double-masked, randomized, placebo-controlled, 7-week clinical trial, according to the poster. The CAC test was given to subjects at 15 minutes, 8 hours and 16 hours after dosing. Patients showed a clinical improvement at all time points after dosing compared with placebo. No serious adverse events were reported in the study.
"These results support twice daily instillation of bepotastine besilate ophthalmic solution 1.5% for relief of ocular itching," Dr. Bergmann and colleagues concluded in the poster.
A separate single clinical site study by T.R. McNamara, MD, and colleagues supported these findings.
Another poster by J.A. Gow, MD, and colleagues showed bepotastine was safe and effective in a healthy pediatric population aged 3 to 9 years old when dosed twice daily for 6 weeks.
A separate poster by J.I. Williams, MD, and colleagues showed bepotastine was effective at reducing eyelid swelling from allergic conjunctivitis as well.